Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 8-K | 10-K | 8-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Molecular Solutions | | | | | | 96.1 | | |
| Diagnostics | | 90.0 | | 65.2 | 78.2 | 85.6 | | |
| OSUR | | | | | | | 92.0 | |
| Other | | 143.6 | | 106.5 | 76.4 | | 75.1 | |
| Total revenues | 0.4 | 233.7 | 0.2 | 171.7 | 154.6 | 181.7 | 167.1 | 128.2 |
| Revenue growth [+] | 65.8% | 36.1% | | 11.1% | -14.9% | 8.8% | 30.3% | 7.1% |
| Diagnostics | | 38.0% | | -16.6% | -8.7% | | | |
| Cost of goods sold | 0.2 | 116.1 | 0.1 | 69.9 | 60.0 | 68.1 | 68.1 | 40.2 |
| Gross profit | 0.1 | 117.6 | 0.1 | 101.9 | 94.6 | 113.6 | 99.0 | 88.0 |
| Gross margin | 38.1% | 50.3% | 50.3% | 59.3% | 61.2% | 62.5% | 59.2% | 68.7% |
| Selling, general and administrative [+] | 0.1 | 44.8 | 0.1 | 34.5 | 31.9 | 68.9 | 57.9 | 58.0 |
| Sales and marketing | 0.0 | 44.8 | 0.0 | 34.5 | 31.9 | 30.6 | 28.5 | 29.7 |
| General and administrative | 0.1 | | 0.1 | | | 38.3 | 29.3 | 28.4 |
| Research and development | 0.0 | | 0.0 | | | 16.3 | 13.4 | 9.8 |
| Other operating expenses | 0.0 | 83.0 | 0.0 | 72.6 | 44.1 | | | |
| EBITDA [+] | | 1.5 | | 4.2 | 26.0 | 34.9 | 33.8 | 26.0 |
| EBITDA growth | -42.4% | -64.5% | | -83.8% | -25.6% | 3.2% | 30.3% | 87.2% |
| EBITDA margin | -1.5% | 0.6% | -4.3% | 2.5% | 16.8% | 19.2% | 20.2% | 20.2% |
| Depreciation | | 8.4 | | 6.1 | 4.8 | 3.8 | 3.4 | 3.1 |
| EBITA | 0.0 | -6.9 | 0.0 | -1.9 | 21.1 | 31.1 | 30.4 | 22.8 |
| EBITA margin | -1.5% | -3.0% | -4.3% | -1.1% | 13.7% | 17.1% | 18.2% | 17.8% |
| Amortization of intangibles | | 3.3 | | 3.2 | 2.5 | 2.6 | 2.6 | 2.5 |
| EBIT [+] | 0.0 | -10.2 | 0.0 | -5.2 | 18.6 | 28.4 | 27.7 | 20.3 |
| EBIT growth | -42.4% | 96.3% | | -127.8% | -34.5% | 2.5% | 36.9% | 151.5% |
| EBIT margin | -1.5% | -4.3% | -4.3% | -3.0% | 12.0% | 15.6% | 16.6% | 15.8% |
| Non-recurring items [+] | 0.0 | | | | | | -12.5 | |
| Asset impairment | 0.0 | | | | | | | |
| Legal settlement | | | | | | | -12.5 | |
| Other income (expense), net [+] | 0.0 | 0.9 | 0.0 | 1.7 | 2.7 | 3.3 | 0.8 | 0.1 |
| Other | 0.0 | | 0.0 | | | 3.3 | 0.8 | 0.1 |
| Pre-tax income | 0.0 | -9.3 | 0.0 | -3.5 | 21.3 | 31.7 | 41.0 | 20.3 |
| Income taxes | 0.0 | 13.7 | 0.0 | 11.4 | 4.7 | 11.3 | 10.1 | 0.6 |
| Tax rate | | | | | 21.9% | 35.7% | 24.6% | 3.0% |
| Net income | 0.0 | -23.0 | 0.0 | -14.9 | 16.7 | 20.4 | 30.9 | 19.7 |
| Net margin | 0.0% | -9.8% | 0.0% | -8.7% | 10.8% | 11.2% | 18.5% | 15.4% |
| |
| Basic EPS [+] | $0.00 | ($0.32) | $0.00 | ($0.22) | $0.27 | $0.33 | $0.52 | $0.35 |
| Growth | | 44.5% | | -181.9% | -19.1% | -36.3% | 47.8% | 144.9% |
| Diluted EPS [+] | $0.00 | ($0.32) | $0.00 | ($0.22) | $0.27 | $0.33 | $0.51 | $0.35 |
| Growth | | 44.5% | | -182.5% | -17.9% | -35.7% | 45.3% | 142.9% |
| |
| Shares outstanding (basic) [+] | 0.1 | 72.0 | 0.1 | 67.5 | 61.7 | 61.1 | 59.1 | 55.6 |
| Growth | 0.7% | 6.6% | | 9.5% | 0.9% | 3.5% | 6.2% | -1.4% |
| Shares outstanding (diluted) [+] | 0.1 | 72.0 | 0.1 | 67.5 | 62.2 | 62.5 | 61.0 | 56.5 |
| Growth | 0.7% | 6.6% | | 8.6% | -0.6% | 2.5% | 8.0% | -0.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|